Aurinia Pharmaceuticals (Nasdaq: AUPH)

A personalized medicine company, that focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. 

It operates through two segments, Diagnostics and Other. The Diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease; identify a patients likelihood of responding to drug therapy; guide a patients dosing to ensure optimal treatment; and assess a patients risk of disease progression and disease recurrence. The Other segment provides testing products and services to the pharmaceutical, biotechnology, and medical research industries; and research and development, and clinical services for patients.  regulatory approvals.

More on AUPH